1. In Vivo

Finding The Balance: First-In-Class Versus Best-In-Class

 
• By Jo Shorthouse

As pharmaceutical companies face a crowded and competitive landscape, the debate between being first-in-class or best-in-class is evergreen. This strategic choice impacts new product launches, with first-to-market therapies offering market share and brand recognition advantages, while best-in-class options can capture value through product differentiation and commercial execution. In Vivo talked to L.E.K. Consulting on how to make a product stand out from the crowd.

Key Takeaways
  1. Strategic Choice Impact: The decision between pursuing a first-in-class or best-in-class strategy is crucial for pharmaceutical companies, as it significantly impacts the success of new product launches. While first-to-market therapies offer advantages in market share and brand recognition, best-in-class options can capture substantial value through differentiation and execution.

As pharmaceutical companies navigate an increasingly crowded and competitive landscape, the age-old debate around whether to be first-in-class or best-in-class...

More from Market Access

More from In Vivo

Deals Shaping The Industry, May 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Podcast: Flagship’s Vision To Predict And Prevent Illness, With Raj Panjabi

 
• By David Wild

Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 
• By Sushmita Panda

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.